1. Home
  2. EMBC vs KURA Comparison

EMBC vs KURA Comparison

Compare EMBC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Embecta Corp.

EMBC

Embecta Corp.

HOLD

Current Price

$5.72

Market Cap

328.1M

Sector

Health Care

ML Signal

HOLD

Logo Kura Oncology Inc.

KURA

Kura Oncology Inc.

SELL

Current Price

$10.56

Market Cap

1.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EMBC
KURA
Founded
1924
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
328.1M
1.1B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
EMBC
KURA
Price
$5.72
$10.56
Analyst Decision
Hold
Strong Buy
Analyst Count
4
15
Target Price
$4.00
★ $32.00
AVG Volume (30 Days)
915.5K
★ 1.7M
Earning Date
11-24-2026
11-03-2026
Dividend Yield
★ 0.71%
N/A
EPS Growth
★ 20.90
N/A
EPS
★ 1.03
N/A
Revenue
N/A
★ $67,482,000.00
Revenue This Year
N/A
$42.46
Revenue Next Year
$5.59
$116.75
P/E Ratio
$5.62
★ N/A
Revenue Growth
N/A
★ 25.24
52 Week Low
$2.77
$7.36
52 Week High
$14.91
$13.90

Technical Indicators

Market Signals
Indicator
EMBC
KURA
Relative Strength Index (RSI) 60.13 37.93
Support Level $4.84 $8.45
Resistance Level $5.91 $12.21
Average True Range (ATR) 0.23 0.48
MACD 0.00 -0.14
Stochastic Oscillator 73.02 13.35

Price Performance

Historical Comparison
EMBC
KURA

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

About KURA Kura Oncology Inc.

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Share on Social Networks: